AEA-P
|
4物価
選択条件：
ブランド
- 富士フイルム和光純薬株式会社(wako)
パッケージ
- 250μg
- 500μg
- 1mg
- 5mg
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY10180
- 製品説明
- 英語製品説明Arachidonoyl Ethanolamide Phosphate
- 包装単位250μg
- 価格￥7000
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY10180
- 製品説明
- 英語製品説明Arachidonoyl Ethanolamide Phosphate
- 包装単位500μg
- 価格￥12600
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY10180
- 製品説明
- 英語製品説明Arachidonoyl Ethanolamide Phosphate
- 包装単位1mg
- 価格￥23800
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY10180
- 製品説明
- 英語製品説明Arachidonoyl Ethanolamide Phosphate
- 包装単位5mg
- 価格￥103900
- 更新しました2024-03-01
- 購入
| 生産者 | 製品番号 | 製品説明 | 包装単位 | 価格 | 更新時間 | 購入 |
|---|---|---|---|---|---|---|
| 富士フイルム和光純薬株式会社(wako) | W01CAY10180 | Arachidonoyl Ethanolamide Phosphate |
250μg | ￥7000 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式会社(wako) | W01CAY10180 | Arachidonoyl Ethanolamide Phosphate |
500μg | ￥12600 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式会社(wako) | W01CAY10180 | Arachidonoyl Ethanolamide Phosphate |
1mg | ￥23800 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式会社(wako) | W01CAY10180 | Arachidonoyl Ethanolamide Phosphate |
5mg | ￥103900 | 2024-03-01 | 購入 |
プロパティ
比重(密度) :1.075±0.06 g/cm3(Predicted)
溶解性 :DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 5 mg/ml
酸解離定数(Pka) :1.86±0.10(Predicted)
溶解性 :DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 5 mg/ml
酸解離定数(Pka) :1.86±0.10(Predicted)
安全情報
| 絵表示(GHS): |
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注意喚起語: | Danger | ||||||||||||||||||||||
| 危険有害性情報: |
|
||||||||||||||||||||||
| 注意書き: |
|
説明
Arachidonoyl ethanolamide (AEA; ) was the first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB1 and CB2) as Δ9-THC . Since that time, a number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol (2-AG; ). The phosphate ester of AEA, AEA-P, has been tested as a water soluble prodrug version of AEA in the treatment of C6 glioma cells in vivo. Here it acts with essentially the same potency as AEA. However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, AEA-P is about 5-fold less potent as an agonist with a Ki of about 200 nM. The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA). However, the effects of AEA-P on the various LPA receptors have not been tested.関連製品価格